{
    "clinical_study": {
        "@rank": "134322", 
        "arm_group": {
            "arm_group_label": "antiviral drug", 
            "arm_group_type": "Experimental", 
            "description": "Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients."
        }, 
        "brief_summary": {
            "textblock": "\u2022\tTo estimate renoprotective efficacy of Telbivudine treated patients with HBV-related liver\n      cirrhosis."
        }, 
        "brief_title": "Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis", 
        "condition": "HBV-related Liver Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects eligible for enrolment in the study must meet all of the following criteria:\n\n          -  Aged between 18-75 years (inclusive).\n\n          -  Male or female.\n\n          -  Subjects with positive HBsAg for more than 6 months and anti-HBs negative regardless\n             of HBeAg status , HBV DNA \u22652\u00d7103 IU/ml\n\n          -  Subjects with HBV-related liver cirrhosis, including compensated cirrhosis and\n             decompensated, but only Child-Pugh A or B.\n\n          -  The ablility to understand and sign a written informed consent prior to any study\n             related procedure and comply with the requirements of the study.\n\n        Exclusion Criteria:\n\n          -  Subjects meeting any of the following criteria must not be enrolled in the study\n\n               -  Subjects with non-HBV cirrhosis\n\n               -  Co-infection with HAV/HCV/HDV/ HIV\n\n               -  Subjects who take nucleosides within 6 months\n\n               -  Kidney injury due to non-HBV factors\n\n               -  Inability to comply with study requirements as determined by the study\n                  investigator\n\n               -  Patients with very low GFR, who may need dialysis or renal transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693679", 
            "org_study_id": "Telbivudine"
        }, 
        "intervention": {
            "arm_group_label": "antiviral drug", 
            "description": "investigational\tTelbivudine,600mg,daily,oral.comparator\tLamivudine,100mg daily,\toral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.", 
            "intervention_name": "Telbivudine, Lamivudine, Adefovir ,Enecavir", 
            "intervention_type": "Drug", 
            "other_name": "no."
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adefovir", 
                "Adefovir dipivoxil", 
                "Lamivudine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Tebivudine  eGFR  non-Tebivudine", 
        "lastchanged_date": "September 24, 2012", 
        "number_of_arms": "1", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Federal Institute for Drugs and Medicinal Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "No.", 
            "measure": "Change from Baseline in glomerular filtration rate and Serum creatinine at 96 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "May 2014"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693679"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Shao-quan Zhang", 
            "investigator_title": "Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "No.", 
            "measure": "Change from Baseline in ALT normalization rate,\u2022 The rate of complications,\u2022 Percentage of participants with HBeAg loss & HBeAg seroconversion and Percentage of subjects achieving HBV DNA<300copies/mL at96 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "May 2014"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shao-quan Zhang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}